Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis - Wu, Qing; Sun, Lulu; Hu, Xiaomin; Wang, Xuemei; Xu, Feng; Chen, Bo; Liang, Xianyi; Xia, Jialin; Wang, Pengcheng; Aibara, Daisuke; Zhang, Shaofei; Zeng, Guangyi; et al. (The Journal of clinical investigation, 2021)
Keywords: Animals; Atherosclerosis; Atherosclerosis - chemically induced; Atherosclerosis - drug therapy; Atherosclerosis - genetics; Atherosclerosis - metabolism; Ceramides - biosynthesis; Ceramides - genetics; Complications and side effects; Development and progression; Diet, High-Fat - adverse effects; Female; Health aspects; Humans; Hypercholesterolemia; Intestinal Mucosa - metabolism; Male; Mice; Mice, Knockout, ApoE; Phosphodiesterases; Physiological aspects; Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors; Receptors, Cytoplasmic and Nuclear - genetics; Receptors, Cytoplasmic and Nuclear - metabolism; Risk factors; Sphingomyelin Phosphodiesterase - genetics; Sphingomyelin Phosphodiesterase - metabolism; Ursodeoxycholic Acid - analogs & derivatives; Ursodeoxycholic Acid - pharmacology; China; Cardiovascular disease; Cardiology; Vascular Biology; Atherosclerosis